About Furiex Pharmaceuticals
Furiex Pharmaceuticals, Inc., a subsidiary of Actavis plc, is a drug development company focusing on treatment for gastroenterology disorders.
Strategic Drug Development Partnerships
Furiex Pharmaceuticals forms collaborations with innovators from both the biotechnology and pharmaceutical industry. The Furiex model has proven success with a strong, diversified product portfolio and pipeline covering multiple therapeutic candidates including clinical-stage assets and two products currently on the market.
Drug development programs are designed and driven by our team of drug development experts, bringing extensive experience across a wide range of therapeutic areas. Our leadership team collectively has more than 75 years of experience. Together, we build value by designing innovative programs that drive development faster and more efficiently across the development timeline.
Furiex Pharmaceuticals was created in response to the biopharmaceutical industry's need for a new drug development model, and our sole purpose is to advance the most promising compounds to the next stage of development quickly. The novel Furiex model uses parallel processing with fewer decision gates. We map predicted outcomes of a study and take risks based on those predictions. Risks are mitigated by our disciplined approach and thoughtful contingency planning for potential issues that may arise. As a result, we can accelerate the drug development process by bridging steps across the developmental program as well as between studies.